AHA honors study of stem cell stroke treatment.
MOUNTAIN VIEW, Calif., February 26, 2017 -- SanBio, Inc., announced that a scientific article featuring its novel stem cell treatment, SB623, for patients following a stroke, was honored by the American Heart Association.
The article was the third prize winner of the 2016 Stroke Progress and Innovation Award.
The awards are presented by Stroke, a scientific journal addressing the diagnosis and treatment of cerebrovascular diseases, jointly with the AHA and American Stroke Association.
Previous award winners have established standards of care in neurology, including Activase (alteplase) and induced hypothermia treatment.
"The results of this study are encouraging to those suffering from the effects of stroke as well as the medical community working to advance treatment options," said CMO Damien Bates.
The clinical trial was a Phase 1/2a, open-label, single-arm, dose escalation study of 18 patients with chronic motor deficits present for at least six months following an ischemic stroke.
Patients received precisely targeted injections of SB623 cells directly into the neural tissue surrounding the damaged area of the brain.
Results for subjects who completed the single arm Phase 1/2a study demonstrated statistically significant improvement in motor function, evaluated using the European Stroke Scale, National Institutes of Health Stroke Scale, the Fugl-Meyer total score and the Fugl-Meyer motor function total score.
The data also showed that the treatment was generally safe and well-tolerated.
Citation: Gary K. Steinberg et al., "Clinical Outcomes of Transplanted Modified Bone Marrow--Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study," Stroke, 2016; STROKEAHA.116.012995, 2 June 2016
Contact: Gary K. Steinberg,
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||News Briefs|
|Publication:||Stem Cell Business News|
|Date:||Mar 6, 2017|
|Previous Article:||U.S. patent covers neuralstem's small molecule compound.|
|Next Article:||Research on RPE cells suggests future treatment for glaucoma patients.|